Sign in Subscribe
Cancer research

New Antibody Therapy Shows Promise in Treating Aggressive, Drug-Resistant Cancers

Strategic Insights

— 1 min read

Researchers at the University of California San Diego School of Medicine have developed a new approach to targeting aggressive, treatment-resistant cancers by optimizing an anti-avb3 antibody that activates macrophages, a type of immune cell already abundant in advanced avb3+ tumors. This innovative therapy has shown promising results in both patient tumor samples and mouse models, offering new hope for patients with advanced cancers.

Key Takeaways:

  • The new anti-avb3 antibody triggers powerful anti-tumor responses by activating macrophages, a type of immune cell already present in advanced avb3+ tumors.
  • The therapy is highly selective and will have no negative impact on surrounding cells, making it a potentially safer alternative to conventional treatments.
  • The study's findings suggest that customizing antibody therapies to target the dominant immune cells present in a given tumor could significantly improve outcomes for patients with aggressive, drug-resistant cancers.
  • The researchers believe that their antibody optimization strategy could be used as a blueprint for treating other treatment-resistant tumors and improving existing immunotherapies.
  • Integrin avb3 is absent in healthy tissues, making the new antibody therapy a more targeted approach.
  • The study was led by Dr. Hiromi I. Wettersten, M.D., Ph.D., an assistant professor in the Department of Pathology at UC San Diego School of Medicine and a member of UC San Diego Moores Cancer Center.
  • The study was funded in part by the National Institutes of Health, Alpha Beta Therapeutics, San Diego Digestive Diseases Research Center, and California Institute for Regenerative Medicine.

Statistics:

  • The study's results suggest that the new antibody therapy could significantly improve outcomes for patients with aggressive, drug-resistant cancers.
  • The integrin avb3 protein is absent in healthy tissues, making the new antibody therapy highly selective.
  • The advanced avb3+ tumors studied in the research already had an abundance of macrophages, which were activated by the new antibody therapy.
  • The study was published in Molecular Cancer Therapeutics.

Sources:

  • University of California San Diego School of Medicine
  • UC San Diego Moores Cancer Center
  • National Institutes of Health
  • Alpha Beta Therapeutics
  • San Diego Digestive Diseases Research Center
  • California Institute for Regenerative Medicine
  • Molecular Cancer Therapeutics

Read more